Comparative Pharmacology
Head-to-head clinical analysis: CHLOROFAIR versus PHISOHEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLOROFAIR versus PHISOHEX.
CHLOROFAIR vs PHISOHEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chloramphenicol inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation.
Disrupts bacterial cell wall synthesis by binding to the bacterial ribosome and inhibiting protein synthesis; also has surfactant properties that disrupt bacterial cell membrane integrity.
125 mg IV every 6 hours for 10 days.
Apply topically as a 3% emulsion to affected area, rinse thoroughly; typically used 1-2 times daily for up to 10 days.
None Documented
None Documented
4.5 hours (prolonged to 10–12 hours in renal impairment)
Terminal elimination half-life approximately 6-7 hours in adults with normal renal function. Prolonged in renal impairment (up to 20 hours) due to reduced clearance of active metabolite (pentachlorophenol).
Renal: 70% unchanged; hepatic metabolism: 25% conjugated; fecal: 5%
Renal (biliary/fecal negligible). Up to 10% of dose excreted unchanged in urine; remainder as metabolites (glucuronide and sulfate conjugates).
Category C
Category C
Antiseptic
Antiseptic